Price to book forward of IRadimed Corp. – LS:A118V4
This article provides financial information for IRadimed Corp. (LS:A118V4), specifically focusing on its price-to-book forward ratio. It includes an overview of the company's financials on TradingView, such as market data provided by ICE Data Services and reference data from FactSet.
IRMD - Iradimed Corp Latest SEC Filings
This article provides the latest SEC filings and a comprehensive overview of Iradimed Corp (IRMD) financials and performance metrics. It details key financial figures such as market cap, income, sales, and various ratios, alongside stock performance, insider and institutional ownership, and analyst recommendations.
Price to book forward of IRadimed Corp. – HAN:46K
This article provides the "Price to book forward" metric for IRadimed Corp. (HAN:46K) trading on the Hannover Stock Exchange. It is a financial data point without further analysis or contextual information.
Enterprise value to revenue forward of IRadimed Corp. – HAN:46K
This article presents the enterprise value to revenue forward for IRadimed Corp. (HAN:46K) as listed on the Hannover Stock Exchange. Although the article provides no specific numerical data, it frames the company's financial metric within the context of a stock exchange listing. The content primarily focuses on navigation, market data sources, and general information about TradingView rather than detailed financial analysis of IRadimed Corp.
IRadimed Corp. Actuals & Estimates (DUS:46K)
This article provides an overview of IRadimed Corp. (DUS:46K) financial actuals and estimates, including income statement, balance sheet, and cash flow data. It covers analyst forecasts for the stock, historical price performance, upcoming earnings dates, and details on past earnings, revenue, net income, dividends, and EBITDA.
46K Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for IRadimed Corp. (46K) stock, based on analyst opinions. It includes details on maximum and minimum price estimates, past financial performance, upcoming earnings dates, dividend information, and company metrics like EBITDA and employee count. The piece also addresses frequently asked questions about trading 46K shares.
IRadimed Corp. Actuals & Estimates (NASDAQ:IRMD)
This article provides an overview of iRadimed Corporation (NASDAQ: IRMD) including financial actuals, estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, earnings, revenue, dividends, and volatility, along with an analyst consensus and technical analysis. The company is set to release its next earnings report on July 30, 2026.
Iradimed (NASDAQ: IRMD) investors approve directors, auditor and pay
Iradimed Corporation's shareholders held their annual meeting, where they elected Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel, and James Hawkins to the board of directors. They also approved RSM US LLP as the independent auditor for the fiscal year ending December 31, 2026, and passed an advisory resolution concerning executive compensation. All proposals received sufficient support from stockholders.
Form 4 Iradimed Co For: 23 June By Investing.com
This article from Investing.com is a regulatory filing update titled "Form 4 Iradimed Co For: 23 June." It reports on the Form 4 filing for Iradimed Co (IRMD) made on June 23rd, 2026, indicating insider transactions for the company. The article contains the title, publication date, and the stock symbol, but no further details about the transactions.
Form 4 Iradimed Co For: 23 June By Investing.com
This article from Investing.com reports that a Form 4 for Iradimed Co was filed on June 23rd. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders, such as directors, officers, and major shareholders, whenever they buy or sell shares of their own company's stock. The article mentions the stock symbol IRMD, indicating a focus on this particular company's insider transactions.
IRADIMED (IRMD) CFO converts RSUs to stock and uses 2,319 shares for taxes
IRADIMED CFO John Glenn converted 5,796 restricted stock units (RSUs) into common shares on June 20, 2026. He then disposed of 2,319 shares to cover tax obligations, which was a tax-withholding transaction, not an open-market sale. Following these transactions, Glenn directly holds 11,937 shares of IRADIMED common stock.
Form 4 Iradimed Co For: 23 June By Investing.com
This article reports on a Form 4 filing for Iradimed Co (IRMD) related to transactions on June 23. While the article's core content is brief, it serves primarily as a placeholder to display current market data and popular news headlines, including updates on EV battery durability, NATO news, and OPEC+ oil output decisions. It also showcases various market indices, commodity prices, and trending stocks.
IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative
IRADIMED (IRMD) is currently valued by one narrative as 21.9% undervalued at $92.20 per share, with a fair value target of $118, primarily due to the anticipated replacement cycle driven by its new 3870 MRI compatible IV pump. While this narrative projects significant revenue growth and improved margins, the company's high P/E ratio of 49.9x compared to peers (37.4x) and a fair ratio of 19x suggests potential valuation risk if sentiment shifts or growth expectations are not met. Investors are encouraged to analyze the risks and rewards, considering both the product upgrade potential and valuation concerns.
IRMD Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for IRadimed Corp (IRMD), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. While some indicators like RSI are neutral or sell, the MACD and several moving averages suggest a bullish outlook. Key support is identified at $89.367 and resistance at $98.087.
IRadimed Corp (IRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for IRadimed Corp (IRMD), indicating an earnings forecast score of 8.00 and ranking 66th in its industry. Analysts, based on 2 ratings, have an average price target of $99.00 with a "Buy" recommendation. The company's previous quarter EPS was $0.51 against an expectation of $0.46, with the next quarter's EPS expected at $0.42 and revenue at $20.35M.
IRadimed Corp (IRMD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for IRadimed Corp (IRMD), highlighting its current risk assessment score of 7.77 and ranking within the Healthcare Equipment & Supplies industry. It details various risk metrics including beta, maximum drawdown, volatility, and Sharpe Ratio, along with liquidity indicators. The report notes the neutral state of the U.S. Dollar Index and its neutral effect on the industry.
IRadimed Corp (IRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a detailed historical overview of IRadimed Corp's (IRMD) dividend payouts, including future declared dividends. It lists the dividend amount, record date, payment date, and ex-dividend date for various interim and final cash dividends. The report also notes that there is no historical data available for stock splits for IRMD.
IRadimed Corp (IRMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of IRadimed Corp (IRMD), listing major individual and institutional holders. It provides a breakdown of shareholder types and traces institutional shareholding trends over several quarters. The data includes the proportion of shares held and changes in holdings for key shareholders and related ETFs.
IRadimed Corp (IRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for IRadimed Corp (IRMD), categorizing its revenue by business segments and geographical regions. As of April 6, 2024, the company's largest revenue contributors are MRI Compatible IV Infusion Pump Systems and MRI Compatible Patient Vital Signs Monitoring Systems. The United States accounts for the significant majority of its regional revenue.
IRadimed Corp (IRMD) Institutional Confidence
IRadimed Corp (IRMD) has an institutional shareholding score of 5.00, placing it 109th in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 65.08%, a 13.11% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 3.45% of outstanding shares.
IRadimed Corp (IRMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IRadimed Corp (IRMD), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, IRMD's price momentum score is 7.36, and the stock is trading between resistance at $98.06 and support at $85.97. Based on the analysis, the overall signal for IRadimed Corp is currently "Sell".
IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial analysis of IRadimed Corp (IRMD), highlighting its strong financial health with a score of 9.60. The company ranks highly in its industry due to robust financial status, high operating efficiency, and significant year-over-year increases in revenue and net profit. The analysis covers various financial dimensions including profitability, quality of earnings, operational efficiency, growth potential, and shareholder returns.
Number of shareholders of IRadimed Corp. – DUS:46K
The article displays an overview of IRadimed Corp. (DUS:46K) on the TradingView platform, focusing on the number of shareholders. It includes sections for financial data, news, community insights, forecasts, and stock information, indicating a market closed status with no recent trades.
IRMD - Iradimed Corp Stock Price and Quote
This page provides a comprehensive overview of Iradimed Corp (IRMD) stock, including its latest closing price, dollar and percentage changes, and various financial metrics such as market cap, income, sales, and P/E ratio. It also details dividend information, employee count, IPO date, and recent insider transactions. Additionally, the page lists recent news articles and analyst ratings for IRMD.
Iradimed director sells $285,000 in company stock By Investing.com
A director at IRADIMED CORP, Hilda Frederique Scharen-Guivel, sold 3,000 shares of company stock for $285,000 on June 4, 2026. This transaction occurred amidst a strong 52% return for IRMD stock over the past year, though InvestingPro's Fair Value analysis suggests the shares may be overvalued. The sale follows a positive first-quarter earnings report where the company surpassed analyst expectations on both EPS and revenue.
Insider Sell: Hilda Scharen-guivel Sells 3,000 Shares of iRadimed Corp (IRMD)
Hilda Scharen-guivel, a Director at iRadimed Corp (IRMD), sold 3,000 shares of the company on June 4, 2026, reducing her holdings to 5,598 shares. This sale contributes to a pattern of 41 insider sells and no buys over the past year. iRadimed Corp, trading at $95 per share, is considered significantly overvalued with a price-to-GF-Value ratio of 1.45, despite providing non-magnetic IV infusion pump systems for MRI procedures.
IRADIMED (IRMD) director sells 3,000 shares in open-market trades
IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions for $95.00 per share on June 4, 2026. This transaction represents a net sale of $285,000 and is categorized as negative filing sentiment. The shares she still holds were acquired through the vesting of restricted stock units related to her board service.
IRMD (NASDAQ: IRMD) files notice to resell 285,000 common shares
Iradimed Corp (IRMD) has filed a Form 144 notice with the SEC, indicating a proposed sale of 285,000 shares of common stock. The filing also notes that 12,783,035 shares were outstanding as of June 4, 2026, and references RSU vesting events in 2023 and 2024. This form serves as a public disclosure of an intended resale of restricted or control securities.
Iradimed corp CEO Roger Susi sells $226,507 in IRMD shares
IRADIMED CORP (NASDAQ:IRMD) CEO Roger E. Susi sold 2,500 shares of common stock totaling $226,507 on June 1, 2026, through the Phillip Susi 2008 Dynasty Trust under a Rule 10b5-1 trading plan. These sales occurred after a strong 61.5% return for IRMD stock and follow the company's Q1 2026 earnings beat with an EPS of $0.49 and revenue of $22 million. Despite positive financial results, the stock saw a pre-market decline, indicating broader investor concerns.
IRADIMED (IRMD) CEO-linked trust sells 2,500 shares under 10b5-1 plan
A trust linked to Roger E. Susi, CEO of IRADIMED (IRMD), indirectly sold 2,500 shares of common stock on June 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in multiple trades at weighted average prices between $88.68 and $91.91. After these transactions, the Phillip Susi 2008 Dynasty Trust still holds 2,164,600 shares, with other trusts linked to Susi holding additional significant amounts.
Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report
Iradimed Corp (NASDAQ: IRMD) reported strong Q1 2026 results, with revenue rising 13% year-over-year and net income jumping 24%. The company also commercially launched its next-generation 3870 MRI-compatible IV infusion pump system, expecting significant shipments in Q2 and accelerated sales in H2 2026. Iradimed provided optimistic Q2 and full-year 2026 guidance, projecting continued revenue growth and GAAP EPS.
IRADIMED CEO’s trust sells 7,500 IRADIMED (IRMD) shares under Rule 10b5-1 plan
Roger E. Susi, CEO of IRADIMED CORP, through the Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of common stock between May 18-19, 2026, at prices ranging from $85.95 to $88.65 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. Despite these sales, the trust retains a significant indirect stake in IRADIMED, and Susi disclaims beneficial ownership beyond his pecuniary interest.
Iradimed CEO Roger Susi sells $657,264 in company stock
Iradimed CEO Roger Susi indirectly sold 7,500 shares of IRADIMED CORP (NASDAQ:IRMD) stock, valued at $657,264, through a Rule 10b5-1 trading plan. These sales occurred on May 18 and May 19, 2026, after the stock experienced a significant 66% return over the past year. Despite recent strong Q1 2026 earnings that exceeded analyst expectations, the stock saw a pre-market decline, signaling investor concerns.
Iradimed CEO Roger Susi sells $657,264 in company stock
Iradimed CEO Roger Susi indirectly sold 7,500 shares of IRADIMED CORP stock for $657,264 between May 18 and May 19, 2026, through a Rule 10b5-1 trading plan. These sales occurred after the stock saw a 66% return over the past year, although analysis suggests it's currently overvalued. Separately, Iradimed reported stronger-than-expected Q1 2026 earnings and revenue, despite a pre-market stock decline indicating investor concerns.
IRADIMED CEO and CFO head to Goldman Sachs health conference in Miami
IRADIMED Corporation announced that its President and CEO, Roger Susi, and CFO, Jack Glenn, will attend the Goldman Sachs 47th Annual Global Healthcare Conference from June 8–10, 2026, in Miami Beach. Interested investors can arrange one-on-one meetings with the management team through their Goldman Sachs representative. This participation is part of IRADIMED's ongoing efforts to engage with investors and highlight its MRI-compatible medical device business after strong financial results.
Iradimed (NASDAQ: IRMD) family trusts disclose 4.45M shares, 34.8% ownership
An amended Schedule 13G/A filing reveals that Roger E. Susi and related family trusts beneficially own 4,450,450 shares, representing 34.8% of Iradimed Corporation's common stock as of April 30, 2026. This aggregate ownership includes shares held by a revocable trust and two dynasty trusts, with specific allocations of sole and shared voting and dispositive powers among family members. The disclosure provides transparency on a significant minority stake and influential voting power within the company.
IRADIMED (IRMD) CEO Susi’s trust sells 7,500 pre-planned shares
IRADIMED's CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of IRMD common stock on May 11 and May 12, 2026. These pre-planned sales, executed under a Rule 10b5-1 trading plan adopted in November 2025, occurred at weighted-average prices in the mid-$80s per share. The filing also notes indirect holdings by other trusts associated with Susi.
The Bull Case For IRADIMED (IRMD) Could Change Following Q1 Results And Reaffirmed 2026 Guidance - Learn Why
IRADIMED (IRMD) recently reported strong Q1 results with sales of US$21.98 million and net income of US$5.82 million, alongside reconfirming its full-year 2026 revenue and GAAP diluted EPS guidance. The company also declared a regular quarterly dividend. This update supports the investment case for IRADIMED, particularly regarding the adoption of its 3870 pump, while concentrating on MRI-compatible pumps remains a key factor to consider.
Iradimed CEO Roger Susi sells $642,861 in company stock
Iradimed CEO Roger Susi sold 7,500 shares of company stock for over $642,000 across May 4 and 5, 2026, under a pre-arranged trading plan. Despite the insider sale, the company recently reported strong first-quarter 2026 earnings, surpassing analyst expectations for both EPS and revenue. Mr. Susi still indirectly holds millions of shares through various trusts.
IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under 10b5-1 plan
IRADIMED CORP CEO Roger E. Susi's family trust sold 7,500 shares of common stock on May 4-5, 2026, for proceeds totaling $642,862. These transactions were pre-scheduled under a Rule 10b5-1 trading plan adopted on November 5, 2025. Susi disclaims beneficial ownership beyond his pecuniary interest.
A Look At IRADIMED (IRMD) Valuation After Q1 2026 Growth, New Pump Rollout And Dividend
IRADIMED (IRMD) reported double-digit revenue and earnings growth for Q1 2026, reaffirmed its full-year guidance, and declared a dividend, along with rolling out its new 3870 MRI infusion pump. While long-term shareholder returns have been strong, short-term momentum has cooled. The company's valuation is mixed, with some metrics suggesting undervaluation at $118.67 fair value due to the new pump's expected market impact, while earnings multiples indicate the stock is significantly overvalued compared to its estimated fair ratio and industry peers.
IRadimed Corporation (NASDAQ:IRMD) Q1 2026 Earnings Call Transcript
IRadimed Corporation reported a strong first quarter for 2026, exceeding earnings expectations with a 13% revenue increase and 33% operating income improvement compared to Q1 2025. The company highlighted the successful product launch of its new 3870 MRI IV pump, noting higher-than-anticipated average selling prices and a surprising number of customers opting for Quad (four-channel) systems, which is driving significant growth in bookings and future revenue. IRadimed reaffirmed its full-year 2026 guidance and declared a quarterly cash dividend, with optimism surrounding the replacement opportunity for its existing installed base of older pump systems.
Is IRADIMED’s 3870 Pump Launch And Reaffirmed Outlook Altering The Investment Case For IRMD?
IRADIMED Corporation (IRMD) recently reported strong Q1 2026 results, including increased sales and net income, alongside the launch of its new 3870 MRI-compatible IV infusion pump. The company reaffirmed its full-year 2026 revenue and EPS guidance, reinforcing the investment narrative around its niche market and the new pump's replacement cycle. While the strong demand for the 3870 pump supports growth, execution risks related to production ramp-up and backlog conversion remain key short-term factors.
IRADIMED (IRMD) Revenue Growth Track Tests Bullish MRI Demand Narratives
IRADIMED (IRMD) is showing consistent profitability with revenue growth, but its stock valuation raises concerns. While revenue and earnings have been strong, the forecast growth rates are slower than historical performance and market expectations. The company's high P/E ratio and valuation gap compared to its DCF fair value highlight potential risks, especially given its reliance on a narrow product range.
iRadimed Corporation (NASDAQ:IRMD) Plans Quarterly Dividend of $0.20
iRadimed Corporation (NASDAQ:IRMD) has announced a quarterly dividend of $0.20 per share, payable on May 29th to shareholders of record by May 15th. This dividend implies a 0.9% yield and a payout ratio of 40.2%, which is well-covered by current earnings. The announcement follows strong Q1 results, where the company surpassed EPS and revenue expectations and provided positive full-year guidance, despite some near-term execution risk due to slightly cautious Q2 revenue guidance.
IRADIMED CORP 1Q 2026: Revenue $21.98M, EPS $0.45— 10-Q Summary
IRADIMED CORP reported its first-quarter 2026 financial results, with revenue reaching $21.98 million and diluted EPS at $0.45, showing an increase compared to the previous year. The growth was primarily driven by higher device sales and improved operating performance, particularly from MRidium IV pump systems and 3880 vital signs monitors. The company also increased its R&D investment for the MRidium 3870 development and improved operating cash flows.
IRADIMED (NASDAQ: IRMD) Q1 2026 revenue rises 13% to $22M
IRADIMED Corporation reported a strong first quarter for 2026, with revenue increasing by 13% to $22.0 million and net income rising to $5.82 million. This growth was primarily fueled by robust sales of MRI-compatible IV infusion pumps and patient monitoring systems, alongside higher amortization from extended maintenance agreements. The company maintained a high gross margin of 77% and declared a quarterly dividend of $0.20 per share, demonstrating solid financial health and commitment to shareholder returns.
IRadimed: Q1 Earnings Snapshot
IRadimed Corp. (IRMD) reported a net income of $5.8 million, or 45 cents per share, for its first quarter, with adjusted earnings of 49 cents per share. The company, which manufactures IV devices for MRI machines, recorded $22 million in revenue for the period. IRadimed provided forward-looking guidance, expecting second-quarter earnings between 44 and 48 cents per share on revenues of $20 million to $21 million, and full-year earnings of $2.06 to $2.21 per share with revenue between $91 million and $96 million.
IRADIMED (NASDAQ: IRMD) Q1 growth, dividend and 2026 outlook
IRADIMED (NASDAQ: IRMD) reported strong first-quarter 2026 results with a 13% revenue increase to $22.0 million and a 22% rise in GAAP diluted EPS to $0.45. The company launched its next-generation 3870 MRI-compatible IV infusion pump and declared a quarterly cash dividend of $0.20 per share. Management also reaffirmed its full-year 2026 revenue guidance of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05, signaling confidence in future growth.
MRI device maker IRADIMED launches new pump as Q1 sales climb 13%
IRADIMED (NASDAQ: IRMD) reported strong first-quarter 2026 financial results, with revenue increasing 13% year-over-year to $22.0 million and record GAAP diluted EPS of $0.45. The company also announced the commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has received encouraging customer reception and strong early orders. IRADIMED reaffirmed its full-year 2026 guidance and declared a quarterly cash dividend of $0.20 per share.
